Omeros Corporation (OMER) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

16/25

Growth 5 Margin 3 Expansion 3 Platform 1 Financial 4

latest quarter score

Earnings Reports

16
Omeros (OMER) Q2 2026: YARTEMLEA Sales Surge 190%, Driving Positive Cash Flow and Capital Structure Strengthening
August 13, 2026
18
Omeros (OMER) Q1 2026: Yartemlia Launch Reaches 30 Sites, Accelerating Standard of Care Ambitions
May 14, 2026
17
Omeros (OMER) Q4 2025: $240M Novo Nordisk Deal and Yartemlia Launch Reset Growth Trajectory
April 01, 2026
9
Omeros (OMER) Q3 2025: $2.1B Novo Nordisk Deal Reshapes Capital and Pipeline Trajectory
November 14, 2025
8
Omeros (OMER) Q2 2025: Debt Reduced by $100M as Narsoplimab Approval Nears
August 15, 2025
9
Omeros (OMER) Q1 2025: $100M Debt Extension Unlocks Launch Path for Narsoplimab
July 03, 2025

Browse all companies